Skip to main content

Fiscal Wizard · Single-issue tearsheet

NVS / Jun 22, 2026 Run #7669

NVS

Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Composite verdict

A 84.0 / 100
Bullish setup · Trend Following 10 drivers · 4 gates blocking
  • Chaikin Money Flow
  • Multi Top/Bottom
  • Coppock Curve
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 1st of 22 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: volatile range
Bull 100%Evidence: High · 16 signals0% Bear
Momentum Bullish 96Mean-reversion Neutral 51

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -76%
Asset value $24.18Earnings power value $75.21Price $147.08

Priced above its no-growth earnings power value ($75.21/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

68.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion 85
Margin of Safety 0
FCF Margin 81
Cash Conversion Cycle 0
Dividend Yield 78
Inventory Turnover 2

Technicals Bullish

99.9 / 100

Bullish setup leads (Chaikin Money Flow, Multi Top/Bottom, Coppock Curve); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 94
Multi Top/Bottom 91
Coppock Curve 88

Risk Gates

4 blocking 2 caution

4 guards active, 23 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for NVS.